Gain Therapeutics, Inc. (GANX): Price and Financial Metrics
GET POWR RATINGS... FREE!
GANX POWR Grades
- Growth is the dimension where GANX ranks best; there it ranks ahead of 43.16% of US stocks.
- GANX's strongest trending metric is Sentiment; it's been moving down over the last 42 days.
- GANX ranks lowest in Momentum; there it ranks in the 6th percentile.
GANX Stock Summary
- GANX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
- GANX's went public 1.86 years ago, making it older than just 6.8% of listed US stocks we're tracking.
- GANX's price/sales ratio is 275.5; that's higher than the P/S ratio of 98.63% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to GAIN THERAPEUTICS INC are FKWL, ACER, DAIO, ALLT, and VTVT.
- Visit GANX's SEC page to see the company's official filings. To visit the company's web site, go to www.gaintherapeutics.com.
GANX Valuation Summary
- In comparison to the median Healthcare stock, GANX's price/earnings ratio is 112.33% lower, now standing at -2.8.
- GANX's price/sales ratio has moved down 4127.8 over the prior 22 months.
Below are key valuation metrics over time for GANX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GANX | 2023-01-20 | 248.1 | 2.0 | -2.8 | -2.2 |
| GANX | 2023-01-19 | 240.4 | 1.9 | -2.7 | -2.1 |
| GANX | 2023-01-18 | 241.0 | 1.9 | -2.7 | -2.1 |
| GANX | 2023-01-17 | 244.3 | 2.0 | -2.8 | -2.2 |
| GANX | 2023-01-13 | 251.9 | 2.0 | -2.9 | -2.3 |
| GANX | 2023-01-12 | 245.9 | 2.0 | -2.8 | -2.2 |
GANX Price Target
For more insight on analysts targets of GANX, see our GANX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $30.00 | Average Broker Recommendation | 1 (Strong Buy) |
GANX Stock Price Chart Interactive Chart >
GANX Price/Volume Stats
| Current price | $3.95 | 52-week high | $6.70 |
| Prev. close | $3.90 | 52-week low | $2.33 |
| Day low | $3.91 | Volume | 30,509 |
| Day high | $4.05 | Avg. volume | 46,280 |
| 50-day MA | $3.34 | Dividend yield | N/A |
| 200-day MA | $3.44 | Market Cap | 46.94M |
Gain Therapeutics, Inc. (GANX) Company Bio
Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Latest GANX News From Around the Web
Below are the latest news stories about GAIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GANX as an investment opportunity.
Sidoti's January Micro-Cap ConferenceSidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. |
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor ConferenceBETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET. A webcast of the presentation |
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue EstimatesGain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business UpdatePresented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer and Appointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securities as of September 30, 2022 Provides Strong Financial Foundation and Extends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, |
Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's ProgramGain Therapeutics Inc (NASDAQ: GANX) announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for Parkinson's Disease. The study was conducted using human-induced pluripotent stem cells (iPSC) derived from donor patients with GBA-associated Parkinson's disease, which were then differentiated into dopaminergic neurons. GT-02287 demonstrated statistically significant, positive effects across a range of meas |
GANX Price Returns
| 1-mo | 26.20% |
| 3-mo | 24.21% |
| 6-mo | -0.50% |
| 1-year | -1.25% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 26.20% |
| 2022 | -42.36% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...